Commercial Physical & Biological Research Industry - SEC Form 4 Insider Trading Screener
Services Sector - Engineering, Accounting, Research, Management Services - Commercial Physical & Biological Research
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Share Price |
Shares Traded |
Shares Owned |
Own chg |
Value Traded |
1d ret |
1w ret |
1m ret |
6m ret |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2017-09-19 | Q | Quintiles Ims Holdings, Inc. | Cpp Investment Board Private Holdings, Inc. | 10% | S - Sale | $94.87 | -6,748,026 | 13,049,669 | -34% | -$640,185,227 | ||||||
2017-09-19 | Q | Quintiles Ims Holdings, Inc. | Danhakl John G | Dir | S - Sale | $94.87 | -720,248 | 4,176,443 | -15% | -$68,329,928 | ||||||
2017-09-19 | Q | Quintiles Ims Holdings, Inc. | Tpg Group Holdings (Sbs) Advisors, Inc. | Dir, 10% | S - Sale | $94.87 | -4,877,974 | 28,285,500 | -15% | -$462,773,393 | ||||||
2017-09-19 | Q | Quintiles Ims Holdings, Inc. | Connaughton John | Dir | S - Sale | $94.87 | -1,030,429 | 6,682,534 | -13% | -$97,756,799 | ||||||
| M | 2017-09-18 | EXEL | Exelixis, Inc. | Papadopoulos Stelios | Dir | S - Sale | $27.68 | -200,000 | 1,044,314 | -16% | -$5,535,387 | |||||
2017-09-20 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $4.23 | +375 | 1,008,500 | 0% | +$1,586 | ||||||
2017-09-18 | INCY | Incyte Corp | Hoppenot Herve | COB , CEO | S - Sale | $119.45 | -70,502 | 299,004 | -19% | -$8,421,464 | ||||||
2017-09-18 | INCR | Inc Research Holdings, Inc. | Gaenzle Christopher L | CAO, GC, Sec | S - Sale | $54.55 | -4,682 | 55,897 | -8% | -$255,427 | ||||||
2017-09-18 | INCR | Inc Research Holdings, Inc. | Rush Gregory S | CFO | S - Sale | $54.48 | -9,703 | 78,593 | -11% | -$528,600 | ||||||
2017-09-18 | INCR | Inc Research Holdings, Inc. | Macdonald Alistair | CEO | S - Sale | $54.60 | -2,348 | 99,453 | -2% | -$128,201 | ||||||
2017-09-18 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $4.40 | +375 | 1,008,125 | 0% | +$1,650 | ||||||
2017-09-14 | EXEL | Exelixis, Inc. | Haley Patrick J. | SVP, Commercial | S - Sale | $27.21 | -60,640 | 75,046 | -45% | -$1,650,014 | ||||||
2017-09-14 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale | $124.25 | -714 | 14,782 | -5% | -$88,715 | ||||||
| M | 2017-09-12 | EXEL | Exelixis, Inc. | Willsey Lance | Dir | S - Sale | $26.88 | -100,000 | 468,273 | -18% | -$2,688,000 | |||||
| D | 2017-09-12 | EXEL | Exelixis, Inc. | Senner Christopher J. | EVP, CFO | S - Sale+OE | $26.79 | -100,000 | 104,798 | -49% | -$2,679,000 | |||||
| DM | 2017-09-12 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $26.90 | -300,000 | 249,718 | -55% | -$8,071,000 | |||||
2017-09-14 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $4.58 | +375 | 1,007,750 | 0% | +$1,718 | ||||||
2017-09-11 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $4.81 | +375 | 1,007,375 | 0% | +$1,804 | ||||||
2017-09-07 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $4.76 | +375 | 1,007,000 | 0% | +$1,785 | ||||||
2017-09-08 | INCY | Incyte Corp | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $132.00 | +100,000 | 942,507 | +12% | +$13,200,000 | ||||||
2017-09-08 | BASI | Bioanalytical Systems Inc | Neff R Matthew | Dir | P - Purchase | $1.50 | +5,000 | 10,000 | +100% | +$7,500 | ||||||
| D | 2017-09-05 | EXAS | Exact Sciences Corp | Lidgard Graham Peter | Chief Science Officer | S - Sale+OE | $40.81 | -75,683 | 343,283 | -18% | -$3,088,801 | |||||
| D | 2017-09-05 | INCY | Incyte Corp | Trower Paul | Principal Accounting Officer | S - Sale+OE | $138.41 | -3,000 | 26,706 | -10% | -$415,230 | |||||
2017-09-05 | CRL | Charles River Laboratories International Inc | Molho Davide | Corporate EVP | S - Sale | $108.43 | -2,668 | 63,566 | -4% | -$289,297 | ||||||
2017-09-05 | CRL | Charles River Laboratories International Inc | Molho Davide | Corporate EVP | S - Sale | $108.06 | -5,889 | 19,217 | -23% | -$636,347 | ||||||
| D | 2017-09-05 | CRL | Charles River Laboratories International Inc | Molho Davide | Corporate EVP | S - Sale+OE | $107.55 | -5,982 | 25,106 | -19% | -$643,373 | |||||
| D | 2017-09-01 | Q | Quintiles Ims Holdings, Inc. | Bousbib Ari | See Remarks | S - Sale+OE | $95.65 | -46,080 | 1,534,061 | -3% | -$4,407,552 | |||||
| D | 2017-09-01 | INCR | Inc Research Holdings, Inc. | Rush Gregory S | CFO | S - Sale+OE | $58.99 | -88,739 | 88,296 | -50% | -$5,234,321 | |||||
| AD | 2017-08-30 | INCR | Inc Research Holdings, Inc. | Rush Gregory S | CFO | S - Sale+OE | $58.26 | -41,420 | 78,296 | -35% | -$2,413,230 | |||||
| D | 2017-09-01 | INCY | Incyte Corp | Siegel Eric H. | EVP, GC | S - Sale+OE | $137.40 | -1,820 | 21,733 | -8% | -$250,068 | |||||
| D | 2017-08-31 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $140.00 | -20,000 | 35,067 | -36% | -$2,800,000 | |||||
2017-09-01 | EXAS | Exact Sciences Corp | Lidgard Graham Peter | Chief Science Officer | S - Sale | $41.49 | -45,775 | 300,966 | -13% | -$1,899,205 | ||||||
| D | 2017-09-01 | INCR | Inc Research Holdings, Inc. | Gaenzle Christopher L | CAO, GC, Sec | S - Sale+OE | $58.67 | -42,601 | 64,824 | -40% | -$2,499,348 | |||||
2017-09-05 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $4.90 | +375 | 1,006,625 | 0% | +$1,838 | ||||||
| D | 2017-08-30 | INCR | Inc Research Holdings, Inc. | Rush Gregory S | CFO | S - Sale+OE | $58.26 | -41,420 | 7,290 | -85% | -$2,413,230 | |||||
| D | 2017-08-29 | INCY | Incyte Corp | Stein Steven H | EVP, Chief Medical Officer | S - Sale+OE | $125.00 | -2,111 | 18,165 | -10% | -$263,875 | |||||
2017-08-31 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $4.48 | +375 | 1,006,250 | 0% | +$1,680 | ||||||
2017-08-28 | Q | Quintiles Ims Holdings, Inc. | Danhakl John G | Dir | S - Sale | $97.33 | -556,968 | 4,896,691 | -10% | -$54,209,695 | ||||||
2017-08-28 | Q | Quintiles Ims Holdings, Inc. | Gillings Dennis B Ph D | Dir | S - Sale | $97.33 | -968,023 | 9,155,906 | -10% | -$94,217,679 | ||||||
2017-08-28 | Q | Quintiles Ims Holdings, Inc. | Tpg Group Holdings (Sbs) Advisors, Inc. | Dir, 10% | S - Sale | $97.33 | -3,772,134 | 33,163,474 | -10% | -$367,141,802 | ||||||
2017-08-28 | Q | Quintiles Ims Holdings, Inc. | Connaughton John | Dir | S - Sale | $97.33 | -833,904 | 7,834,970 | -10% | -$81,163,876 | ||||||
2017-08-28 | Q | Quintiles Ims Holdings, Inc. | Cpp Investment Board Private Holdings, Inc. | 10% | S - Sale | $97.33 | -5,218,245 | 15,299,011 | -25% | -$507,891,786 | ||||||
2017-08-28 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $4.44 | +375 | 1,005,875 | 0% | +$1,665 | ||||||
| D | 2017-08-25 | Q | Quintiles Ims Holdings, Inc. | Erlinger III James H | See Remarks | S - Sale+OE | $98.96 | -10,000 | 17,340 | -37% | -$989,600 | |||||
| D | 2017-08-25 | Q | Quintiles Ims Holdings, Inc. | Knightly Kevin C | See Remarks | S - Sale+OE | $99.51 | -19,339 | 24,351 | -44% | -$1,924,429 | |||||
| D | 2017-08-17 | USRM | U.S. Stem Cell, Inc. | Murphy William P Jr | Dir | P - Purchase | $0.03 | +1,799,614 | 5,112,600 | +54% | +$49,849 | |||||
2017-08-24 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $4.54 | +375 | 1,005,500 | 0% | +$1,703 | ||||||
2017-08-22 | XON | Intrexon Corp | Gupta Vinita D | Dir | P - Purchase | $17.61 | +3,000 | 5,839 | +106% | +$52,830 | ||||||
2017-08-22 | XON | Intrexon Corp | Shapiro Robert B | Dir | P - Purchase | $17.50 | +2,850 | 126,123 | +2% | +$49,883 | ||||||
2017-08-18 | BASI | Bioanalytical Systems Inc | Davis Gregory Cole | Dir | P - Purchase | $1.70 | +5,000 | 5,000 | New | +$8,500 | ||||||
2017-08-18 | BASI | Bioanalytical Systems Inc | Neff R Matthew | Dir | P - Purchase | $1.70 | +5,000 | 5,000 | New | +$8,500 | ||||||
2017-08-22 | MEDP | Medpace Holdings, Inc. | Medpace Limited Partnership | 10% | S - Sale | $30.27 | -2,000,000 | 20,999,997 | -9% | -$60,540,000 | ||||||
2017-08-21 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $4.07 | +375 | 1,005,125 | 0% | +$1,526 | ||||||
| D | 2017-08-17 | INCR | Inc Research Holdings, Inc. | Macdonald Alistair | CEO | S - Sale+OE | $55.65 | -8,828 | 101,801 | -8% | -$491,261 | |||||
2017-08-17 | CRL | Charles River Laboratories International Inc | Barbo William D | Corporate EVP, CCO | S - Sale | $99.91 | -4,000 | 16,924 | -19% | -$399,632 | ||||||
2017-08-18 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $3.81 | +375 | 1,004,750 | 0% | +$1,429 | ||||||
2017-08-17 | EXAS | Exact Sciences Corp | Carey Thomas D. | Dir | P - Purchase | $37.71 | +2,500 | 60,858 | +4% | +$94,275 | ||||||
2017-08-17 | PIRS | Pieris Pharmaceuticals, Inc. | Geraghty James A | Dir | P - Purchase | $4.82 | +10,000 | 10,000 | New | +$48,200 | ||||||
| M | 2017-08-16 | PIRS | Pieris Pharmaceuticals, Inc. | Reine Allan | See Remarks | P - Purchase | $4.82 | +65,000 | 65,000 | New | +$313,350 | |||||
2017-08-14 | PRAH | Pra Health Sciences, Inc. | Kkr Pra Investors L.P. | 10% | S - Sale | $74.85 | -9,500,000 | 13,195,984 | -42% | -$711,075,000 | ||||||
2017-08-14 | PRAH | Pra Health Sciences, Inc. | Shannon Colin | Pres, CEO | S - Sale | $74.85 | -400,000 | 0 | -100% | -$29,940,000 | ||||||
2017-08-14 | PRAH | Pra Health Sciences, Inc. | Baddour Linda | EVP, CFO | S - Sale | $74.85 | -100,000 | 0 | -100% | -$7,485,000 | ||||||
| D | 2017-08-14 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale+OE | $67.10 | -2,552 | 11,671 | -18% | -$171,228 | |||||
2017-08-11 | XON | Intrexon Corp | Kindler Jeffrey B | Dir | P - Purchase | $18.32 | +5,440 | 71,762 | +8% | +$99,661 | ||||||
2017-08-14 | XON | Intrexon Corp | Last Andrew J. | COO | P - Purchase | $19.99 | +2,000 | 2,000 | New | +$39,980 | ||||||
2017-08-11 | CASC | Cascadian Therapeutics, Inc. | Myers Scott Dunseth | Pres, CEO | P - Purchase | $3.73 | +5,500 | 49,716 | +12% | +$20,543 | ||||||
2017-08-14 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $3.70 | +375 | 1,004,375 | 0% | +$1,388 | ||||||
2017-08-11 | XON | Intrexon Corp | Kirk Randal J | CEO, 10% | P - Purchase | $18.85 | +132,625 | 56,400,156 | 0% | +$2,499,981 | ||||||
2017-08-11 | XON | Intrexon Corp | Nimrodi Nir | SVP-Corporate Development | P - Purchase | $18.75 | +3,369 | 7,369 | +84% | +$63,169 | ||||||
2017-08-11 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $3.55 | +750 | 1,004,000 | 0% | +$2,663 | ||||||
| D | 2017-08-09 | Q | Quintiles Ims Holdings, Inc. | Knightly Kevin C | See Remarks | S - Sale+OE | $90.28 | -20,000 | 26,826 | -43% | -$1,805,600 | |||||
2017-08-11 | XON | Intrexon Corp | Lehr Donald P. | GC | P - Purchase | $18.33 | +1,094 | 28,249 | +4% | +$20,053 | ||||||
2017-08-11 | XON | Intrexon Corp | Perez Jeffrey Thomas | SVP, IP Affairs | P - Purchase | $17.89 | +1,000 | 12,537 | +9% | +$17,890 | ||||||
2017-08-11 | XON | Intrexon Corp | Mitchell Dean J | Dir | P - Purchase | $18.33 | +5,000 | 18,103 | +38% | +$91,640 | ||||||
| D | 2017-08-07 | Q | Quintiles Ims Holdings, Inc. | Bousbib Ari | See Remarks | S - Sale+OE | $90.35 | -92,160 | 1,534,061 | -6% | -$8,326,656 | |||||
| D | 2017-08-04 | INCY | Incyte Corp | Trower Paul | Principal Accounting Officer | S - Sale+OE | $125.25 | -3,000 | 26,706 | -10% | -$375,750 | |||||
| D | 2017-08-01 | INCY | Incyte Corp | Siegel Eric H. | EVP, GC | S - Sale+OE | $132.92 | -1,820 | 21,733 | -8% | -$241,914 | |||||
| D | 2017-07-31 | EXAS | Exact Sciences Corp | Elliott Jeffrey Thomas | CFO | S - Sale+OE | $39.41 | -5,846 | 14,487 | -29% | -$230,391 | |||||
| D | 2017-07-20 | INCY | Incyte Corp | Stein Steven H | EVP, Chief Medical Officer | S - Sale+OE | $131.09 | -6,485 | 18,165 | -26% | -$850,119 | |||||
2017-07-17 | CRL | Charles River Laboratories International Inc | Massaro George | Dir | S - Sale | $101.38 | -200 | 14,701 | -1% | -$20,276 | ||||||
| D | 2017-07-17 | CRL | Charles River Laboratories International Inc | Massaro George | Dir | S - Sale+OE | $100.81 | -3,830 | 14,901 | -20% | -$386,103 | |||||
2017-06-30 | HPPI | Hedgepath Pharmaceuticals, Inc. | Hedgepath, LLC | 10% | S - Sale | $0.00 | -2,500,000 | 79,627,069 | -3% | -$0 | ||||||
2017-07-10 | CRL | Charles River Laboratories International Inc | Foster James C | COB, Pres, CEO | S - Sale | $100.02 | -500 | 346,518 | 0% | -$50,008 | ||||||
2017-07-10 | CRL | Charles River Laboratories International Inc | Foster James C | COB, Pres, CEO | S - Sale | $99.30 | -5,720 | 336,678 | -2% | -$568,011 | ||||||
2017-07-10 | CRL | Charles River Laboratories International Inc | Foster James C | COB, Pres, CEO | S - Sale | $99.07 | -9,264 | 342,398 | -3% | -$917,818 | ||||||
2017-07-10 | CRL | Charles River Laboratories International Inc | Foster James C | COB, Pres, CEO | S - Sale | $98.92 | -9,516 | 351,662 | -3% | -$941,337 | ||||||
| D | 2017-07-05 | INCY | Incyte Corp | Trower Paul | Principal Accounting Officer | S - Sale+OE | $126.18 | -3,000 | 12,148 | -20% | -$378,540 | |||||
| D | 2017-07-03 | INCY | Incyte Corp | Siegel Eric H. | EVP, GC | S - Sale+OE | $126.20 | -1,820 | 18,216 | -9% | -$229,684 | |||||
| D | 2017-07-03 | EXAS | Exact Sciences Corp | Coward D Scott | SVP, GC | S - Sale+OE | $35.21 | -1,987 | 63,666 | -3% | -$69,962 | |||||
| D | 2017-06-30 | INCY | Incyte Corp | Gryska David W | EVP, CFO | S - Sale+OE | $129.74 | -599 | 19,015 | -3% | -$77,714 | |||||
| DM | 2017-06-30 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.08 | -2,785 | 32,600 | -8% | -$75,430 | |||||
| DM | 2017-07-03 | INCR | Inc Research Holdings, Inc. | Gaenzle Christopher L | CAO, GC, Sec | S - Sale+OE | $58.32 | -6,873 | 46,494 | -13% | -$400,846 | |||||
| DM | 2017-06-30 | INCR | Inc Research Holdings, Inc. | Macdonald Alistair | CEO | S - Sale+OE | $58.38 | -10,555 | 73,380 | -13% | -$616,159 | |||||
| D | 2017-06-29 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.00 | -846 | 32,600 | -3% | -$22,842 | |||||
| DM | 2017-06-27 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.13 | -5,059 | 32,600 | -13% | -$137,241 | |||||
| DM | 2017-06-23 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.18 | -9,635 | 32,600 | -23% | -$261,918 | |||||
| D | 2017-06-22 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.25 | -209 | 32,600 | -1% | -$5,696 | |||||
| D | 2017-06-22 | CRL | Charles River Laboratories International Inc | Foster James C | COB, Pres, CEO | S - Sale+OE | $100.00 | -43,154 | 371,518 | -10% | -$4,315,400 | |||||
| D | 2017-06-22 | CRL | Charles River Laboratories International Inc | Molho Davide | Corporate EVP | S - Sale+OE | $100.00 | -10,948 | 63,566 | -15% | -$1,094,800 | |||||
| DM | 2017-06-20 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $27.38 | -2,159 | 32,600 | -6% | -$59,113 |
Real-time CSV? Options? Alerts? Contact us!
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |